🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Recruitingn/aAges any - anyAllPeking University People's Hospital
NCT06211166 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring. * Neutrophil engraftment * Received at least one MRD monitoring by digital PCR after HSCT Exclusion Criteria: * Patients who relapsed or died before the first digital PCR monitoring * Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
💊

What it tests

  • Digital PCR
  • Quantitative PCR
  • MFC
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy